“This PROFICIENCY conference comes at a time of great interest in this area and should prove very valuable to those who attend,” said Akiyoshi Uchiyama, M.D., Ph.D., former board member and deputy director of GlaxoSmithKline Japan.
TOKYO, JAPAN (PRWEB) September 11, 2014
ERT, a leading global solution provider for high-quality patient safety and efficacy endpoint data collection, today opened registration for its PROFICIENCY conference in Tokyo, Japan. The educational conference, which takes place October 14, 2014 at the Shinagawa Prince Hotel, focuses on developing, implementing, and justifying effective strategies for collecting high quality Clinical Outcome Assessment (COA) data in clinical research.
The conference will offer current and relevant information that addresses the evaluation of safety and efficacy of new medical products in clinical development and beyond. Practical international regulatory and industry trends will be reviewed, leaving attendees with actionable takeaways to help optimize success throughout the product life cycle.
“Biopharmaceutical researchers throughout Japan and Asia are eager to learn how COA data can help them meet their clinical objectives,” said Akiyoshi Uchiyama, M.D., Ph.D., former board member and deputy director of GlaxoSmithKline Japan. “This PROFICIENCY conference comes at a time of great interest in this area and should prove very valuable to those who attend.”
Attendees of the Tokyo PROFICIENCY Conference will have the opportunity to network with their peers and a faculty comprised of leading international biopharmaceutical and industry experts. A sample of confirmed speakers includes:
- Kenneth Kaitin, Ph.D., Director and Professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine
- Akiyoshi Uchiyama, M.D., Ph.D., Artage and Parkside Hiroo Ladies Clinic
- Chad Gwaltney, Ph.D., Chief Scientist and Regulatory Advisor, Endpoints, ERT
- Jill V. Platko, Ph.D., ePRO Lead, Patient Reported Outcomes Group, Associate Director, Global Health Economics and Outcomes Research, Covance
- Satoshi Azuta, Sr. Project Manager, ERT
“The Tokyo PROFICIENCY Conference will address the increasingly complex challenges of developing and bringing new medical products to market,” said Minako Kogoma, Representative Director, ERT Asia Group, Ltd. “We’re very excited to address these important topics and to exchange various ideas of new opportunities with our clients and partners.”
For more information and to register for the meeting, please visit http://www.ertjapan.jp.
ERT (http://www.ert.com) is a leading provider of high-quality patient safety and efficacy endpoint data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services, and consulting that increase the accuracy and reliability of patient data and improve the efficiency of the clinical development process throughout the product lifecycle. ERT delivers the most widely deployed solutions in centralized cardiac safety, respiratory services, suicide risk assessment and Clinical Outcome Assessments (COAs) – which includes patient, clinician, and observer reported outcomes. By efficiently integrating these solutions through a system built upon a scientific and regulatory foundation, ERT collects, analyzes, and delivers safety and efficacy data critical to the approval, labeling, and reimbursement of pharmaceutical products. ERT is a global organization with headquarters in Philadelphia, PA and offices throughout the U.S., U.K., Japan, and Germany.